EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Blood biomarkers differentiate AD‐related versus non‐AD‐related cognitive deficits

Kelsey R Sewell iD, Lauren E Oberlin, Thomas K Karikari, Marcos Olvera-Rojas, Lu Wan, Jill K Morris, Paul J Kueck, Xuemei Zeng, Haiqing Huang, George Grove, Yijun Chen, Tara K Lafferty und 10 weitere

Alzheimer's & Dementia · 2025-03 · 21 (3)

DOI: 10.1002/alz.14619 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 20.03.2025. Verfasst von Kelsey R Sewell und 21 weiteren Autor:innen. Beteiligte Einrichtung: AdventHealth Research Institute, Neuroscience, Orlando, Florida, USA. Hauptthemen laut MEDLINE: Biomarkers, Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NIMH NIH HHS, Kansas University infrastructure.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION The utility of blood‐based biomarkers for discriminating Alzheimer's disease (AD)‐related versus non‐AD‐related cognitive deficits in preclinical populations remains poorly understood. Here, we tested the capability of blood markers to detect and discriminate variation in performance across multiple cognitive domains in a cognitively unimpaired sample. METHODS Participants ( n = 648, aged 69.9 ± 3.8, 71% female) underwent a comprehensive cognitive assessment and assays for plasma‐based biomarkers amyloid beta (Aβ)1‐42/1‐40 by mass spectrometry, phosphorylated tau (p‐tau) 181 and 217, p‐tau217/Aβ1‐42, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL). RESULTS Greater p‐tau217 was exclusively associated with poorer episodic memory performance (β = −0.11, SE = 0.04, p = .003), and remained so after covarying for NfL. Higher NfL was non‐specifically associated with poorer performance across a range of cognitive domains and remained so after covarying for p‐tau217. DISCUSSION Blood‐based biomarkers may differentiate non‐AD‐related versus AD‐related cognitive deficits. This characterization will be important for early intervention and disease monitoring for AD. Highlights There is heterogeneity in the causes of cognitive decline in aging. AD‐related blood biomarkers may help characterize these causes. Elevated p‐tau217 was exclusively associated with poorer episodic memory. Elevated NfL was associated with poorer cognition in a broad range of domains. Blood biomarkers may help differentiate AD‐ and non‐AD‐related cognitive deficits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BiomarkersAlzheimer DiseaseCognitive DysfunctionHumansFemaleMaleAgedAmyloid beta-Peptidestau ProteinsNeurofilament ProteinsNeuropsychological TestsGlial Fibrillary Acidic ProteinMiddle AgedPeptide FragmentsMemory, Episodic

Stichwörter der Autor:innen

Alzheimer's diseasebiomarkersblood‐based biomarkerscognitioncognitive function

Substanzen

BiomarkersAmyloid beta-Peptidestau ProteinsNeurofilament Proteinsneurofilament protein LGlial Fibrillary Acidic ProteinPeptide Fragments

Autor:innen und Institutionen

  • AdventHealth Research Institute, Neuroscience, Orlando, Florida, USA.
  • Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, Western Australia, Australia.
  • Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York, USA.
  • Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Physical Education and Sports, Faculty of Sport Sciences, Sport and Health University Research Institute (iMUDS), University of Granada, Granada, Spain.
  • Alzheimer's Disease Research Center, University of Kansas, Kansas City, Kansas, USA.

ORCID-Profile: Kelsey R Sewell

Förderung

  • NIA NIH HHS
  • NIMH NIH HHS
  • Kansas University infrastructure
  • University of Pittsburgh
  • NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health

Zitieren

APA

Sewell, K. R., Oberlin, L. E., Karikari, T. K., Olvera-Rojas, M., Wan, L., Morris, J. K., Kueck, P. J., Zeng, X., Huang, H., Grove, G., Chen, Y., Lafferty, T. K., Sehrawat, A., Kamboh, M. I., Marsland, A. L., Kramer, A. F., McAuley, E., Burns, J. M., Hillman, C. H., …, & Erickson, K. I. (2025). Blood biomarkers differentiate AD‐related versus non‐AD‐related cognitive deficits. Alzheimer's & Dementia, 21(3). https://doi.org/10.1002/alz.14619

Vancouver

Sewell KR, Oberlin LE, Karikari TK, Olvera-Rojas M, Wan L, Morris JK, et al. Blood biomarkers differentiate AD‐related versus non‐AD‐related cognitive deficits. Alzheimer's & Dementia. 2025;21(3). doi:10.1002/alz.14619

BibTeX
@article{Sewell2025,
  author = {Sewell, Kelsey R and Oberlin, Lauren E and Karikari, Thomas K and Olvera-Rojas, Marcos and Wan, Lu and Morris, Jill K and Kueck, Paul J and Zeng, Xuemei and Huang, Haiqing and Grove, George and Chen, Yijun and Lafferty, Tara K and Sehrawat, Anuradha and Kamboh, M Ilyas and Marsland, Anna L and Kramer, Arthur F and McAuley, Edward and Burns, Jeffrey M and Hillman, Charles H and Vidoni, Eric D and Kang, Chaeryon and Erickson, Kirk I},
  title = {Blood biomarkers differentiate AD‐related versus non‐AD‐related cognitive deficits},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {3},
  doi = {10.1002/alz.14619}
}
Kostenlos starten →